Connor, Clark & Lunn Investment Management (CC&L)
IMRX icon

Connor, Clark & Lunn Investment Management (CC&L)’s Immuneering IMRX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3M Buy
601,255
+200,892
+50% +$1.02M 0.01% 882
2026
Q1 		$2.11M Buy
400,363
+267,683
+202% +$1.37M ﹤0.01% 946
2025
Q4 		$873K Buy
+132,680
New +$852K ﹤0.01% 1181

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s IMRX Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its Immuneering (IMRX) stake by 50% in Q2 2026, buying an estimated $1.02M and bringing the position to 601,255 shares worth $3M. The position accounts for 0.01% of the portfolio, ranked #882.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in IMRX in Q4 2025 and has held it in 3 quarters since. 111 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 601,255 shares of Immuneering worth $3M as of Q2 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) bought 200,892 Immuneering shares in Q2 2026, an estimated $1.02M.
  • Immuneering made up 0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #882 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Immuneering in Q4 2025 and has held it in 3 quarters since.
  • 111 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.